Following in the footsteps of several pharma companies, life sciences giant Thermo Fisher is doubling down on investments at ...

The top 20 biopharmas demonstrated a strong start to 2025, despite ongoing uncertainty surrounding Trump’s tariffs.

MSD is also bracing for a $200m hit due to tariffs as it accelerates US manufacturing and shifts its global supply strategy.

CDMOs are crucial partners in alum-based vaccine production, managing aseptic filling with precision and efficiency.

Pharmaceutical companies in Europe are requesting the EU to adopt drug pricing strategies comparable to the US.

AstraZeneca, Tempus and Pathos will develop an AI-driven foundational model to develop therapeutics in oncology.

Biogen Netherlands has received marketing authorisation from the UK MHRA for its Skyclarys to treat Friedreich's ataxia.